Teva Pharmaceutical Industries Ltd. has entered into a definitive agreement to acquire CoGenesys, Inc. for $400 million cash. CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. CoGenesys was established in 2005 as a division of Human Genome Sciences Inc. (HGSI) with an early drug development focus and became independent in June 2006.     The acquisition is part of Teva’s strategic goal to advance in the biogenerics market as it e...